Cancer-associated KBTBD4 mutations induce differentiation defects and confer a unique therapeutic vulnerability.

doi:10.1038/s41417-026-01068-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cancer-associated KBTBD4 mutations induce differentiation defects and confer a unique therapeutic vulnerability.

Cancer gene therapy - 1 Sept 2026

Sivaprasad Rohit, Žemaitis Kristijonas, Linfeldt David, Ghosh Sudip, de Snaijer Anne, Magnusson Mattias, Ek Fredrik, Hansson Jenny, Subramaniam Agatheeswaran

Abstract excerpt

Epigenetic regulation governs stem cell fate and perturbations in these mechanisms often lead to tumor development. The CoREST complex, a critical regulator of neural and hematopoietic stem cell differentiation, is recurrently targeted by gain of function mutations in the ubiquitin ligase KBTBD4 in high-risk embryonal brain tumors. However, the tumorigenic potential of these mutations remains unresolved partly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Differentiation
Share to Hematopoietic Stem Cells
Share to Histone Deacetylase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice

Share to Mutation

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 42576054
DOI: 10.1038/s41417-026-01068-x
PMCID: PMC13518216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.